Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Infection screening in newly arrived Afghan sanctuary seekers - a family-centred approach.

BMC health services research·2026
Same author

High Prevalence of Hepatitis B Virus Infection Among People Living with Advanced HIV Disease in Botswana.

Biomedicines·2026
Same author

Detection of Hepatitis B Virus in Cerebrospinal Fluid of People with HIV-associated Cryptococcal Meningitis in Botswana.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Long-Acting Treatment and Advanced HIV Disease - Addressing a Public Health Priority.

The New England journal of medicine·2026
Same author

Cause of Death and Risk of Death for People Living With HIV Admitted to Hospital: A Systematic Review and Meta-Analysis.

Journal of the International AIDS Society·2026
Same author

Cytomegalovirus viremia in advanced HIV disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Use of gloves: current evidence vs. current use.

Current opinion in infectious diseases·2026
Same journal

Understanding challenges to prevention of healthcare related infections.

Current opinion in infectious diseases·2026
Same journal

Harnessing next-generation microbial diagnostics to optimize infection management in immunocompromised hosts.

Current opinion in infectious diseases·2026
Same journal

Epidemiology, treatment and outcomes of antimicrobial-resistant infections in hematopoietic stem cell transplant recipients.

Current opinion in infectious diseases·2026
Same journal

Dengue and chikungunya vaccines past, present and future: implications for travelers.

Current opinion in infectious diseases·2026
Same journal

Oropouche virus: viral evolution, epidemiological trends, and challenges for control.

Current opinion in infectious diseases·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens
06:03

Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens

Published on: September 20, 2024

Cryptococcal immune reconstitution inflammatory syndrome.

Nicky Longley1, Thomas S Harrison, Joseph N Jarvis

  • 1Research Centre for Infection and Immunity, Division of Clinical Sciences, St. George's University of London, London, UK.

Current Opinion in Infectious Diseases
|December 18, 2012
PubMed
Summary
This summary is machine-generated.

Cryptococcal immune reconstitution inflammatory syndrome (CM-IRIS) management is improved by understanding risk factors and optimizing antifungal therapy with antiretroviral therapy (ART) timing. Early recognition and prevention strategies can reduce mortality.

Related Experiment Videos

Last Updated: May 16, 2026

Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens
06:03

Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens

Published on: September 20, 2024

Area of Science:

  • Infectious Diseases
  • Immunology
  • Public Health

Background:

  • Cryptococcal immune reconstitution inflammatory syndrome (CM-IRIS) is a significant concern in HIV patients initiating antiretroviral therapy (ART).
  • Understanding the epidemiology, pathogenesis, and risk factors is crucial for effective management and prevention.

Purpose of the Study:

  • To review the epidemiology, pathogenesis, and risk factors of CM-IRIS.
  • To emphasize how new insights inform rational management and prevention strategies.

Main Methods:

  • Literature review of existing studies on CM-IRIS.
  • Analysis of risk factors, including baseline CD4 counts, inflammatory response, and organism/antigen load.
  • Evaluation of current and proposed management and prevention strategies.

Main Results:

  • Risk factors for paradoxical CM-IRIS include low baseline CD4 counts, rapid immune restoration, and high fungal/antigen loads.
  • Rapidly fungicidal induction therapy and prompt ART initiation (around 3 weeks) may reduce mortality.
  • Early recognition and management of CM-IRIS are associated with reduced mortality.
  • Unmasking CM-IRIS is preventable through cryptococcal antigen screening and preemptive antifungal treatment.

Conclusions:

  • Optimal antifungal induction and judicious ART timing are key to reducing paradoxical CM-IRIS mortality.
  • Early recognition, prompt management, and exclusion of alternative diagnoses are essential.
  • Screening for cryptococcal antigen before ART initiation can prevent unmasking CM-IRIS.